Picture Berlin Partner Voices Robinson Data for Precision Medicine 650x100px

Person › Details

Stéphane Boissel (SparingVision SAS)

Boissel, Stéphane (SparingVision 202010– CEO before Sangamo + TxCell + Genclis + Transgene + Innate Pharma + Lazard)

	Organisation	SparingVision SAS
	Former/major organisation	TxCell S.A. (Euronext Paris: TXCL)
	Product	SPVN06 mutation-agnostic AAV gene therapy for ofretinitis pigmentosa (SparingVision)
	Product 2	gene therapy

Record changed: 2023-07-12

Picture Berlin Partner Voices Robinson Data for Precision Medicine 650x200px

More documents for Stéphane Boissel

[1] SparingVision SAS. (7/12/23). "Press Release: SparingVision Sells Ex Vivo GIRK Technology to Tenpoint Therapeutics". Paris....
[2] SparingVision SAS. (9/14/22). "Press Release: SparingVision Raises €75 Million Series B to Continue Building World-Leading Portfolio of Genomic Medicines for Ocular Diseases"....
[3] Intellia Therapeutics, Inc.. (10/13/21). "Press Release: Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology". Cambridge, MA & Paris....
[4] SparingVision SAS. (4/20/21). "Press Release: SparingVision Expands Novel Ocular Disease Pipeline with Acquisition of Gamut Therapeutics". Paris....
[5] SparingVision SAS. (10/21/20). "Press Release: SparingVision Raises €44.5 Million and Appoints Stéphane Boissel as Chief Executive Officer". Paris....
[6] Sangamo Therapeutics, Inc.. (7/23/18). "Press Release: Sangamo Therapeutics to Acquire TxCell". Richmond, CA & Valbonne....
[7] TxCell S.A.. (7/9/18). "Press Release: TxCell Exercises In-license Option to the University of British Columbia's Intellectual Property Rights of the HLA-A2 CAR-Treg Program". Valbonne....
[8] TxCell S.A.. (5/31/18). "Press Release: TxCell Names Lonza as Its CAR-Treg Cellular Product Manufacturer". Valbonne & Basel....
[9] TxCell S.A.. (12/18/17). "Press Release: TxCell Completes CAR-Treg Manufacturing Process Development and Provides Update to CMO Selection". Valbonne....
[10] TxCell S.A.. (10/25/17). "Press Release: TxCell Renegotiates OCABSA Financing Option to Extend Cash Runway [Not for distribution in the United States of America, Canada, Australia and Japan]". Valbonne....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]